These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26851042)

  • 1. Prognostic Significance of Preoperative Urine Cytology in Low-grade Non-muscle-invasive Bladder Cancer.
    Kiyoshima K; Akitake M; Shiota M; Takeuchi A; Takahashi R; Inokuchi J; Tatsugami K; Yokomizo A; Eto M
    Anticancer Res; 2016 Feb; 36(2):799-802. PubMed ID: 26851042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder.
    Reis LO; Taheri D; Chaux A; Guner G; Mendoza Rodriguez MA; Bivalacqua TJ; Schoenberg MP; Epstein JI; Netto GJ
    Hum Pathol; 2016 Jan; 47(1):20-5. PubMed ID: 26520419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The significance of urine cytology three consecutive days after transurethral resection as a predictor of superficial bladder cancer recurrence].
    Yumura Y; Takase K; Kato Y; Hamano A; Mikata K; Ogo Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Mar; 50(3):171-6. PubMed ID: 15148768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of positive urine cytology on progression and cancer-specific mortality of non--muscle-invasive bladder cancer.
    Koga F; Kobayashi S; Fujii Y; Ishioka J; Yokoyama M; Nakanishi Y; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
    Clin Genitourin Cancer; 2014 Jun; 12(3):e87-93. PubMed ID: 24169493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma.
    Kobayashi Y; Saika T; Miyaji Y; Saegusa M; Arata R; Akebi N; Takenaka T; Manabe D; Nasu Y; Kumon H
    World J Urol; 2012 Apr; 30(2):271-5. PubMed ID: 21805177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study.
    Tanaka N; Kikuchi E; Kanao K; Matsumoto K; Shirotake S; Kobayashi H; Miyazaki Y; Ide H; Obata J; Hoshino K; Hayakawa N; Kosaka T; Oyama M; Miyajima A; Momma T; Nakagawa K; Jinzaki M; Nakajima Y; Oya M
    Urol Oncol; 2014 Jan; 32(1):48.e19-26. PubMed ID: 24055429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.
    Lodde M; Mian C; Mayr R; Comploj E; Trenti E; Melotti R; Campodonico F; Maffezzini M; Fritsche HM; Pycha A
    Int J Urol; 2014 Oct; 21(10):968-72. PubMed ID: 24947145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer.
    Shin YS; Kim SD; Cha JS; Kim MK; Jeong YB; Kim HJ
    Int J Urol; 2011 Jun; 18(6):439-43. PubMed ID: 21481014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of preoperative pyuria in patients with non-muscle-invasive bladder cancer.
    Satake N; Ohno Y; Nakashima J; Ohori M; Tachibana M
    Int J Urol; 2015 Jul; 22(7):645-9. PubMed ID: 25912166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical seeding of upper urinary tract urothelial carcinoma cells during nephroureterectomy: an exploratory analysis from the THPMG trial.
    Ito A; Shintaku I; Satoh M; Ioritani N; Tochigi T; Numata I; Namima T; Kambe K; Kyan A; Ueno S; Katoh S; Adachi H; Yamashita S; Yamaguchi T; Arai Y;
    Jpn J Clin Oncol; 2013 Nov; 43(11):1139-44. PubMed ID: 24006504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical recurrence after surgical management of urothelial carcinoma of the upper urinary tract.
    Hirano D; Okada Y; Nagane Y; Satoh K; Mochida J; Yamanaka Y; Hirakata H; Yamaguchi K; Kawata N; Takahashi S; Henmi A
    Urol Int; 2012; 89(1):71-7. PubMed ID: 22677699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for bladder recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Cho DS; Kim SI; Ahn HS; Kim SJ
    Urol Int; 2013; 91(2):153-9. PubMed ID: 23391941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34.
    Ajili F; Kacem M; Tounsi H; Darouiche A; Enayfer E; Chebi M; Manai M; Boubaker S
    Ultrastruct Pathol; 2012 Oct; 36(5):336-42. PubMed ID: 22574784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system.
    Nishiyama N; Kitamura H; Maeda T; Takahashi S; Masumori N; Hasegawa T; Tsukamoto T
    Jpn J Clin Oncol; 2013 Nov; 43(11):1124-31. PubMed ID: 23980236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
    Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
    Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.